NSE: ERIS | BSE: 540596

Turnaround Potential

Download real time

1768.10 -2.90 (-0.16%)

61.15% Gain from 52W Low

29,089 NSE+BSE Volume

NSE 03 Sep, 2025 12:36 PM (IST)

24,083.9

Market Cap

High in industry

0.4

Beta 1Year

Very Low volatility

Eris Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ERIS, BSE:540596 Eris Lifesciences Ltd.

Search Inside the pdf :

Eris Lifesciences Ltd.

06 Aug 2025

1768.10

-0.16%

Eris Lifesciences (ERIS IN) Q1FY26 Result Update Revenue...

Buy: Eris Lifesciences Ltd.

Target

Prabhudas Lilladhar

Eris Lifesciences' (ERIS) Q1FY26 EBITDA was broadly in line with our estimate (Rs2.75bn; up 11% YoY). Though Q1FY26 revenue growth (up 7.4% YoY) was muted, we see pick up in coming quarters as insulin shortages stabilize, export pick up and likely additional market share gain from human insulin market. Eris has opted for inorganic route to diversify and scale up existing portfolio. This has been implemented without diluting margins. We expect margins to scale up from the current level of 35% in FY25 as revenue scales up from recent...

Number of FII/FPI investors increased from 178 to 193 in Jun 2025 qtr.

Eris Lifesciences Ltd.

20 May 2025

1768.10

-0.16%

Eris Lifesciences (ERIS IN) Q4FY25 Result Update Multiple...

Buy: Eris Lifesciences Ltd.

Target

Prabhudas Lilladhar

Strong FY26 guidance with +15% revenue growth with 36% OPM. up 70% YoY). Eris has opted for inorganic route to diversify and scale up expect margins to scale up from the current level of 35% as revenue scales up from recent acquisitions, which are currently operating at sub-optimal profitability. The company has multiple growth levers such as broad-based...

Number of FII/FPI investors increased from 178 to 193 in Jun 2025 qtr.

Eris Lifesciences Ltd.

19 May 2025

1768.10

-0.16%

Lower-than-est. 4Q due to supply disruption for select products

Neutral: Eris Lifesciences Ltd.

Target

Motilal Oswal

Eris Lifesciences (ERIS) posted lower-than-expected 4QFY25 performance. This has been largely due to a marginal slip in the execution, particularly in the insulin revenue.

Promoters unpledged 1.58% of shares in last quarter. Total pledge stands at 16.93% of promoter holdings

Eris Lifesciences Ltd.

05 Feb 2025

1768.10

-0.16%

Eris Lifesciences (BUY): First player to launch GLP products in India

Buy: Eris Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

Base domestic growth at 12% vs IMP growth of 8% due to new product launches and price increase

Number of FII/FPI investors increased from 178 to 193 in Jun 2025 qtr.

Eris Lifesciences Ltd.

05 Feb 2025

1768.10

-0.16%